Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: a prospective cohort study

dc.contributor.author
Nicolás, David
dc.contributor.author
Suárez, Antonio
dc.contributor.author
Ambrosioni, Juan
dc.contributor.author
Manzardo, Christian
dc.contributor.author
Ligero, Carmen
dc.contributor.author
Costa, Josep
dc.contributor.author
Fernández, Emma
dc.contributor.author
Marcos, Ma. Angeles
dc.contributor.author
Plana Prades, Montserrat
dc.contributor.author
Mosquera, Maria Mar
dc.contributor.author
Sánchez-Palomino, Sonsoles
dc.contributor.author
Gatell, José M.
dc.contributor.author
Miró Meda, José M. (José María), 1956-
dc.date.issued
2020-05-19T21:16:50Z
dc.date.issued
2020-05-19T21:16:50Z
dc.date.issued
2019-08-03
dc.date.issued
2020-05-19T21:16:50Z
dc.identifier
1201-9712
dc.identifier
https://hdl.handle.net/2445/161478
dc.identifier
691892
dc.description.abstract
Background: Severe cases of primary HIV infection have been described in patients presenting with neurological involvement, AIDS defining events or other life-threatening events. These severe forms have not been fully studied. Objectives: To determine the prevalence and characteristics of severe PHI in a hospital-based cohort of primary HIV infection, and the response to the early initiation of antiretroviral therapy (ART) at 12 months. Methods: Every patient with PHI attending Hospital Clínic of Barcelona (1997-2015) was evaluated. Severe PHI was defined using clinical, analytical and immunological criteria. Chi-squared test was used for categorical variables and Student's t-test for quantitative variables. Results: 33% of 224 PHI patients (95% CI: 26.84%-39.16%) had a severe PHI. These patients had more symptoms, abnormal analytical parameters and hospital admissions. The severe PHI group had a significantly higher viral load although no differences were observed at 12 months in terms of viral suppression or CD4 count recovery. None died during PHI. Conclusions: Up to one third of patients in our cohort presented with a severe PHI, which was associated with higher hospitalization rates and higher plasma HIV RNA viral load. However, severe forms were not associated to a worse clinical, immunological or virological outcome at 12 months.
dc.format
7 p.
dc.format
application/pdf
dc.language
eng
dc.publisher
Elsevier B.V.
dc.relation
Reproducció del document publicat a: https://doi.org/10.1016/j.ijid.2019.08.001
dc.relation
International Journal of Infectious Diseases, 2019, vol. 88, p. 73-79
dc.relation
https://doi.org/10.1016/j.ijid.2019.08.001
dc.rights
cc-by-nc-nd (c) Nicolás, David et al., 2019
dc.rights
http://creativecommons.org/licenses/by-nc-nd/3.0/es
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Articles publicats en revistes (Fonaments Clínics)
dc.subject
Infeccions per VIH
dc.subject
Pacients amb lesions cerebrals
dc.subject
Antiretrovirals
dc.subject
HIV infections
dc.subject
Brain damage patients
dc.subject
Antiretroviral agents
dc.title
Prevalence, clinical characteristics and outcome of severe primary HIV-1 infection: a prospective cohort study
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)